FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891875730> ?p ?o ?g. }

• W2891875730 endingPage "766" @default.
• W2891875730 startingPage "759" @default.
• W2891875730 abstract "With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and possible uses of tocilizumab in the field of ophthalmology. We performed a search for records reporting the use of tocilizumab for various diseases in MEDLINE (PubMed and OVID). We conducted an analysis of several individual studies and their reported individual patient data (82 eyes of 45 patients) published from 2011 to 2017. Tocilizumab may prove to be an effective choice for the treatment of a variety of ocular conditions such as refractory uveitis, inflammatory macular edema, vitreo-retinal tumors and thyroid orbitopathy, leading to control of the inflammation in these patients. Further studies need to be conducted to establish its safety and efficacy. Les uvéites sont une des causes principales de cécité dans le monde, et les thérapies biologiques ont apparues comme une option pour le traitement des cas réfractaires en tenant compte des bons résultats obtenus dans la clinique. L’objectif de cette étude est de réaliser une révision systématique de la connaissance actuelle du rôle et des possibles applications du tocilizumab en ophtalmologie. Une recherche des rapports d’utilisation du tocilizumab pour des différentes maladies a été effectuée sur MEDLINE (PubMed et OVID). Une analyse de plusieurs études individuelles a été faite sur 82 yeux de 45 patients, publiés du 2011 au 2017. Le Tocilizumab peut être le traitement de choix pour certaines pathologies oculaires comme les uvéites réfractaires, l’œdème maculaire réfractaire, les tumeurs vitréo-rétiniennes et l’orbitopathie thyroïdienne, aidant à contrôler l’inflammation de ces patients. Des études complémentaire doivent être conduites pour établir l’efficacité et la sécurité de ce produit." @default.
• W2891875730 created "2018-09-27" @default.
• W2891875730 creator A5009030595 @default.
• W2891875730 creator A5026174967 @default.
• W2891875730 creator A5048139998 @default.
• W2891875730 creator A5049519291 @default.
• W2891875730 creator A5073369979 @default.
• W2891875730 creator A5082788246 @default.
• W2891875730 creator A5091099964 @default.
• W2891875730 date "2018-10-01" @default.
• W2891875730 modified "2023-10-18" @default.
• W2891875730 title "The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative" @default.
• W2891875730 cites W1566194239 @default.
• W2891875730 cites W1796417290 @default.
• W2891875730 cites W1972017473 @default.
• W2891875730 cites W1974162532 @default.
• W2891875730 cites W1975525636 @default.
• W2891875730 cites W1989029085 @default.
• W2891875730 cites W1992502382 @default.
• W2891875730 cites W1994098895 @default.
• W2891875730 cites W1997564030 @default.
• W2891875730 cites W1999157521 @default.
• W2891875730 cites W1999622952 @default.
• W2891875730 cites W2006142366 @default.
• W2891875730 cites W2017213437 @default.
• W2891875730 cites W2021329940 @default.
• W2891875730 cites W2024029731 @default.
• W2891875730 cites W2026800023 @default.
• W2891875730 cites W2028597677 @default.
• W2891875730 cites W2043412985 @default.
• W2891875730 cites W2045952946 @default.
• W2891875730 cites W2052604117 @default.
• W2891875730 cites W2063634757 @default.
• W2891875730 cites W2065329061 @default.
• W2891875730 cites W2070393459 @default.
• W2891875730 cites W2071008401 @default.
• W2891875730 cites W2083681450 @default.
• W2891875730 cites W2087013294 @default.
• W2891875730 cites W2087769239 @default.
• W2891875730 cites W2091816507 @default.
• W2891875730 cites W2092364221 @default.
• W2891875730 cites W2096564629 @default.
• W2891875730 cites W2098914621 @default.
• W2891875730 cites W2099402970 @default.
• W2891875730 cites W2108373994 @default.
• W2891875730 cites W2109781015 @default.
• W2891875730 cites W2110736568 @default.
• W2891875730 cites W2111615368 @default.
• W2891875730 cites W2112901522 @default.
• W2891875730 cites W2116724316 @default.
• W2891875730 cites W2118877038 @default.
• W2891875730 cites W2120852203 @default.
• W2891875730 cites W2139499737 @default.
• W2891875730 cites W2150411992 @default.
• W2891875730 cites W2150952126 @default.
• W2891875730 cites W2154984288 @default.
• W2891875730 cites W2158064334 @default.
• W2891875730 cites W2159574407 @default.
• W2891875730 cites W2161089446 @default.
• W2891875730 cites W2170111382 @default.
• W2891875730 cites W2171355496 @default.
• W2891875730 cites W2171799063 @default.
• W2891875730 cites W2304411752 @default.
• W2891875730 cites W2308906418 @default.
• W2891875730 cites W2323405758 @default.
• W2891875730 cites W2325478548 @default.
• W2891875730 cites W2614732086 @default.
• W2891875730 cites W2615678025 @default.
• W2891875730 doi "https://doi.org/10.1016/j.jfo.2018.02.006" @default.
• W2891875730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30217605" @default.
• W2891875730 hasPublicationYear "2018" @default.
• W2891875730 type Work @default.
• W2891875730 sameAs 2891875730 @default.
• W2891875730 citedByCount "11" @default.
• W2891875730 countsByYear W28918757302019 @default.
• W2891875730 countsByYear W28918757302020 @default.
• W2891875730 countsByYear W28918757302021 @default.
• W2891875730 countsByYear W28918757302023 @default.
• W2891875730 crossrefType "journal-article" @default.
• W2891875730 hasAuthorship W2891875730A5009030595 @default.
• W2891875730 hasAuthorship W2891875730A5026174967 @default.
• W2891875730 hasAuthorship W2891875730A5048139998 @default.
• W2891875730 hasAuthorship W2891875730A5049519291 @default.
• W2891875730 hasAuthorship W2891875730A5073369979 @default.
• W2891875730 hasAuthorship W2891875730A5082788246 @default.
• W2891875730 hasAuthorship W2891875730A5091099964 @default.
• W2891875730 hasConcept C118487528 @default.
• W2891875730 hasConcept C119767625 @default.
• W2891875730 hasConcept C121332964 @default.
• W2891875730 hasConcept C126322002 @default.
• W2891875730 hasConcept C141071460 @default.
• W2891875730 hasConcept C142424586 @default.
• W2891875730 hasConcept C16005928 @default.
• W2891875730 hasConcept C17744445 @default.
• W2891875730 hasConcept C199539241 @default.
• W2891875730 hasConcept C2776194053 @default.
• W2891875730 hasConcept C2776652619 @default.
• W2891875730 hasConcept C2776685619 @default.

• next